摘要: In the 1980s monoclonal antibodies promised an era of “magic” bullet therapies that could specifically kill tumor cells while leaving healthy tissues intact. But need to covalently couple killing agent (toxin, radioisotopes, etc.) limited their clinical potential. Now, new bispecific (BsAbs, or bi-functional antibodies) have been developed. The prototypic BsAb consists two different specific binding sites, with one directed target antigen on surface cells, and other a trigger molecule.
springer.com
sci-hub.se 参考文章(84)
P Ely, PK Wallace, AL Givan, RF Graziano, PM Guyre, MW Fanger, Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma Blood. ,vol. 87, pp. 3813- 3821 ,(1996) , 10.1182/BLOOD.V87.9.3813.BLOODJOURNAL8793813
C Renner, S Ohnesorge, G Held, S Bauer, W Jung, JP Pfitzenmeier, M Pfreundschuh, T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28 Blood. ,vol. 88, pp. 236- 241 ,(1996) , 10.1182/BLOOD.V88.1.236.BLOODJOURNAL881236
C Demanet, J Brissinck, J De Jonge, K Thielemans, Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation Blood. ,vol. 87, pp. 4390- 4398 ,(1996) , 10.1182/BLOOD.V87.10.4390.BLOODJOURNAL87104390
K Sundarapandiyan, J Goldstein, R F Graziano, C Somasundaram, Y M Deo, Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein. Journal of Immunology. ,vol. 158, pp. 872- 879 ,(1997)
W.D. Mallender, E.W. Voss, Construction, expression, and activity of a bivalent bispecific single-chain antibody. Journal of Biological Chemistry. ,vol. 269, pp. 199- 206 ,(1994) , 10.1016/S0021-9258(17)42334-9
IA Haagen, AJ Geerars, WB de Lau, BJ Bast, BC de Gast, The Efficacy of CD3 x CD19 Bispecific Monoclonal Antibody (BsAb) in a Clonogenic Assay: The Effect of Repeated Addition of BsAb and Interleukin-2 Blood. ,vol. 85, pp. 3208- 3212 ,(1995) , 10.1182/BLOOD.V85.11.3208.BLOODJOURNAL85113208
Bertram Eichentopf, Michael Kloft, Michael Pfreundschuh, Frank Hartmann, Christoph Renner, Wolfram Jung, Christina Deisting, Marietta Juwana, Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody Blood. ,vol. 89, pp. 2042- 2047 ,(1997) , 10.1182/BLOOD.V89.6.2042
G J Weiner, S A Kostelny, B K Link, J Y Tso, J R Hillstrom, M S Cole, S L Wang, The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. Journal of Immunology. ,vol. 152, pp. 2385- 2392 ,(1994)
Sonja Van Meirvenne, Carlo Heirman, Marijke de Veerman, Oberdan Leo, Muriel Moser, Joost Kiewiet De Jonge, Kris Thielemans, IN VIVO RETARGETING OF T CELL EFFECTOR FUNCTION BY RECOMBINANT BISPECIFIC SINGLE CHAIN FV (ANTI-CD3 X ANTI-IDIOTYPE) INDUCES LONG-TERM SURVIVAL IN THE MURINE BCL1 LYMPHOMA MODEL Journal of Immunology. ,vol. 161, pp. 1454- 1461 ,(1998)
M S Cole, J Y Tso, S A Kostelny, Formation of a bispecific antibody by the use of leucine zippers. Journal of Immunology. ,vol. 148, pp. 1547- 1553 ,(1992)